Bristol's bad news is good for rivals: analysts MarketWatch By Val Brickates Kennedy, MarketWatch. BOSTON (MarketWatch) â€" Bristol-Myers Squibb's bad news that its hepatitis C drug INX-189 might be a dud is good news for rival drug developers, analysts said Thursday. Late Wednesday, Bristol (NYSE:BMY) ... |
Friday, August 3, 2012
Bristol's bad news is good for rivals: analysts - MarketWatch
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment